JP2009515949A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009515949A5 JP2009515949A5 JP2008541107A JP2008541107A JP2009515949A5 JP 2009515949 A5 JP2009515949 A5 JP 2009515949A5 JP 2008541107 A JP2008541107 A JP 2008541107A JP 2008541107 A JP2008541107 A JP 2008541107A JP 2009515949 A5 JP2009515949 A5 JP 2009515949A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- heterocycloalkyl
- aryl
- heteroaryl
- heteroarylalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 86
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 82
- 125000000753 cycloalkyl group Chemical group 0.000 claims 73
- 125000003118 aryl group Chemical group 0.000 claims 72
- 125000001072 heteroaryl group Chemical group 0.000 claims 71
- 125000003710 aryl alkyl group Chemical group 0.000 claims 70
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 70
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 58
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 58
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 54
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 53
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 40
- 125000005843 halogen group Chemical group 0.000 claims 32
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 13
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 8
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 7
- 125000000304 alkynyl group Chemical group 0.000 claims 7
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 208000024827 Alzheimer disease Diseases 0.000 claims 5
- 238000001727 in vivo Methods 0.000 claims 5
- 239000002243 precursor Substances 0.000 claims 5
- 125000003282 alkyl amino group Chemical group 0.000 claims 4
- 125000004663 dialkyl amino group Chemical group 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 2
- PFWVTHUDSZRCTO-UHFFFAOYSA-N 2-amino-1-methyl-5-(2-phenylethyl)pyrimidin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.O=C1N=C(N)N(C)C=C1CCC1=CC=CC=C1 PFWVTHUDSZRCTO-UHFFFAOYSA-N 0.000 claims 1
- QRZKQTGJCKDSGN-UHFFFAOYSA-N 2-amino-3,5-dimethyl-6-(2-phenylethyl)pyrimidin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N1=C(N)N(C)C(=O)C(C)=C1CCC1=CC=CC=C1 QRZKQTGJCKDSGN-UHFFFAOYSA-N 0.000 claims 1
- UMPOTDYQEMLZRZ-UHFFFAOYSA-N 2-amino-3-methyl-5-(2-phenylethyl)pyrimidin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.O=C1N(C)C(N)=NC=C1CCC1=CC=CC=C1 UMPOTDYQEMLZRZ-UHFFFAOYSA-N 0.000 claims 1
- NTOOSRIQBIMWSJ-UHFFFAOYSA-N 2-amino-3-methyl-5-phenyl-6-(2-phenylethyl)pyrimidin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=CC=CC=1C=1C(=O)N(C)C(N)=NC=1CCC1=CC=CC=C1 NTOOSRIQBIMWSJ-UHFFFAOYSA-N 0.000 claims 1
- MALAKURYZJFBLT-UHFFFAOYSA-N 2-amino-3-methyl-6-(2-phenylethyl)pyrimidin-4-one Chemical compound O=C1N(C)C(N)=NC(CCC=2C=CC=CC=2)=C1 MALAKURYZJFBLT-UHFFFAOYSA-N 0.000 claims 1
- NEKSSFOSVQFARB-UHFFFAOYSA-N 2-amino-4-(3-bromo-4-chlorophenyl)-4,5-dimethyl-1,5-dihydropyrimidin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CC1C(=O)NC(N)=NC1(C)C1=CC=C(Cl)C(Br)=C1 NEKSSFOSVQFARB-UHFFFAOYSA-N 0.000 claims 1
- GZPIUMLCUOIOIU-UHFFFAOYSA-N 2-amino-5-(2-phenylethyl)-1h-pyrimidin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.O=C1NC(N)=NC=C1CCC1=CC=CC=C1 GZPIUMLCUOIOIU-UHFFFAOYSA-N 0.000 claims 1
- XMKDVXUWXNFCOG-UHFFFAOYSA-N 2-amino-5-[2-[3-(3-methoxyphenyl)phenyl]ethyl]-1h-pyrimidin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(CCC=3C(NC(N)=NC=3)=O)C=CC=2)=C1 XMKDVXUWXNFCOG-UHFFFAOYSA-N 0.000 claims 1
- PLXBBXSHAWKMPQ-UHFFFAOYSA-N 2-amino-5-[2-[3-(3-methoxyphenyl)phenyl]ethyl]-3-methylpyrimidin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(CCC=3C(N(C)C(N)=NC=3)=O)C=CC=2)=C1 PLXBBXSHAWKMPQ-UHFFFAOYSA-N 0.000 claims 1
- UJZKVDNGADIRTE-UHFFFAOYSA-N 2-amino-5-benzyl-6-[2-(3-bromophenyl)ethyl]-3-methylpyrimidin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=CC=CC=1CC=1C(=O)N(C)C(N)=NC=1CCC1=CC=CC(Br)=C1 UJZKVDNGADIRTE-UHFFFAOYSA-N 0.000 claims 1
- HUUIHHSBUQUGQT-UHFFFAOYSA-N 2-amino-5-benzyl-6-[2-[3-(3-methoxyphenyl)phenyl]ethyl]-3-methylpyrimidin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(CCC3=C(C(=O)N(C)C(N)=N3)CC=3C=CC=CC=3)C=CC=2)=C1 HUUIHHSBUQUGQT-UHFFFAOYSA-N 0.000 claims 1
- BVQRDQHLQSWFKK-UHFFFAOYSA-N 2-amino-5-bromo-3-methyl-6-(2-phenylethyl)pyrimidin-4-one Chemical compound O=C1N(C)C(N)=NC(CCC=2C=CC=CC=2)=C1Br BVQRDQHLQSWFKK-UHFFFAOYSA-N 0.000 claims 1
- CNBSPUGFNQVSJS-UHFFFAOYSA-N 2-amino-6-(2-phenylethyl)-1h-pyrimidin-4-one Chemical compound N1C(N)=NC(=O)C=C1CCC1=CC=CC=C1 CNBSPUGFNQVSJS-UHFFFAOYSA-N 0.000 claims 1
- BSFYBPPWNXZIPH-UHFFFAOYSA-N 2-amino-6-[2-(3-bromophenyl)ethyl]-1h-pyrimidin-4-one Chemical compound O=C1NC(N)=NC(CCC=2C=C(Br)C=CC=2)=C1 BSFYBPPWNXZIPH-UHFFFAOYSA-N 0.000 claims 1
- QZJVGUKULLSSCO-UHFFFAOYSA-N 2-amino-6-[2-(3-bromophenyl)ethyl]-3,5-dimethylpyrimidin-4-one Chemical compound N1=C(N)N(C)C(=O)C(C)=C1CCC1=CC=CC(Br)=C1 QZJVGUKULLSSCO-UHFFFAOYSA-N 0.000 claims 1
- MUWOCUNRCCSVTE-UHFFFAOYSA-N 2-amino-6-[2-(3-bromophenyl)ethyl]-5-methyl-1h-pyrimidin-4-one Chemical compound N1=C(N)NC(=O)C(C)=C1CCC1=CC=CC(Br)=C1 MUWOCUNRCCSVTE-UHFFFAOYSA-N 0.000 claims 1
- DTBQCGNZLPFKJS-UHFFFAOYSA-N 2-amino-6-[2-[3-(3-methoxyphenyl)phenyl]ethyl]-3,5-dimethylpyrimidin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(CCC3=C(C(=O)N(C)C(N)=N3)C)C=CC=2)=C1 DTBQCGNZLPFKJS-UHFFFAOYSA-N 0.000 claims 1
- SXFTZSKTVNASQO-UHFFFAOYSA-N 2-amino-6-[2-[3-(furan-2-yl)phenyl]ethyl]-3,5-dimethylpyrimidin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N1=C(N)N(C)C(=O)C(C)=C1CCC1=CC=CC(C=2OC=CC=2)=C1 SXFTZSKTVNASQO-UHFFFAOYSA-N 0.000 claims 1
- VDDYOHIPPWWPQC-UHFFFAOYSA-N 2-amino-8-[(3-bromophenyl)methyl]-3,8-dimethyl-6,7-dihydro-5h-quinazolin-4-one Chemical compound O=C1N(C)C(N)=NC2=C1CCCC2(C)CC1=CC=CC(Br)=C1 VDDYOHIPPWWPQC-UHFFFAOYSA-N 0.000 claims 1
- NXTSOXXYMHVMIN-UHFFFAOYSA-N 2-amino-8-[(3-bromophenyl)methyl]-3-methyl-5,6,7,8-tetrahydroquinazolin-4-one Chemical compound C1CCC=2C(=O)N(C)C(N)=NC=2C1CC1=CC=CC(Br)=C1 NXTSOXXYMHVMIN-UHFFFAOYSA-N 0.000 claims 1
- YAVQQCQABYEAMN-UHFFFAOYSA-N 2-amino-8-[(3-bromophenyl)methyl]-5,6,7,8-tetrahydro-1h-quinazolin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=2NC(N)=NC(=O)C=2CCCC1CC1=CC=CC(Br)=C1 YAVQQCQABYEAMN-UHFFFAOYSA-N 0.000 claims 1
- XKOANOLURVHUGM-UHFFFAOYSA-N 2-amino-8-[(3-bromophenyl)methyl]-8-methyl-1,5,6,7-tetrahydroquinazolin-4-one Chemical compound C1CCC(C(NC(N)=N2)=O)=C2C1(C)CC1=CC=CC(Br)=C1 XKOANOLURVHUGM-UHFFFAOYSA-N 0.000 claims 1
- QDUPIWKQAWTULW-UHFFFAOYSA-N 2-amino-8-[[3-(3-methoxyphenyl)phenyl]methyl]-3,8-dimethyl-6,7-dihydro-5h-quinazolin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(CC3(C)C4=C(C(N(C)C(N)=N4)=O)CCC3)C=CC=2)=C1 QDUPIWKQAWTULW-UHFFFAOYSA-N 0.000 claims 1
- OPBNBRSINBFTFT-UHFFFAOYSA-N 2-amino-8-[[3-(3-methoxyphenyl)phenyl]methyl]-3-methyl-5,6,7,8-tetrahydroquinazolin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(CC3C4=C(C(N(C)C(N)=N4)=O)CCC3)C=CC=2)=C1 OPBNBRSINBFTFT-UHFFFAOYSA-N 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010036631 Presenile dementia Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 0 *C1=C(*)N=C(N)N(*)C1=O Chemical compound *C1=C(*)N=C(N)N(*)C1=O 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73732605P | 2005-11-15 | 2005-11-15 | |
| PCT/SE2006/001280 WO2007058580A1 (en) | 2005-11-15 | 2006-11-13 | Novel 2-aminopyrimidinone derivatives and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009515949A JP2009515949A (ja) | 2009-04-16 |
| JP2009515949A5 true JP2009515949A5 (OSRAM) | 2010-01-07 |
Family
ID=38048893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008541107A Pending JP2009515949A (ja) | 2005-11-15 | 2006-11-13 | 新規な２−アミノピリミジノン誘導体およびそれらの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20090215801A9 (OSRAM) |
| EP (1) | EP1951680A4 (OSRAM) |
| JP (1) | JP2009515949A (OSRAM) |
| CN (1) | CN101360720A (OSRAM) |
| WO (1) | WO2007058580A1 (OSRAM) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| PE20070135A1 (es) | 2005-06-14 | 2007-03-09 | Schering Corp | Compuestos heterociclicos como inhibidores de aspartil proteasas |
| KR101052122B1 (ko) | 2005-10-25 | 2011-07-26 | 시오노기세야쿠 가부시키가이샤 | 아미노디히드로티아진 유도체 |
| TW200815349A (en) | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
| EP2151435A4 (en) | 2007-04-24 | 2011-09-14 | Shionogi & Co | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| EP2147914B1 (en) | 2007-04-24 | 2014-06-04 | Shionogi&Co., Ltd. | Aminodihydrothiazine derivatives substituted with cyclic groups |
| MX2010013256A (es) | 2008-06-13 | 2010-12-21 | Shionogi & Co | Derivado heterociclico que contiene azufre que tiene actividad inhibitoria de beta-secretasa. |
| PE20110303A1 (es) | 2008-09-11 | 2011-05-21 | Pfizer | Derivados de heteroaril acetamidas como activadores de glucoquinasa |
| JPWO2010047372A1 (ja) | 2008-10-22 | 2012-03-22 | 塩野義製薬株式会社 | Ｂａｃｅ１阻害活性を有する２−アミノピリミジン−４−オンおよび２−アミノピリジン誘導体 |
| TW201020244A (en) | 2008-11-14 | 2010-06-01 | Astrazeneca Ab | New compounds |
| JP2012515760A (ja) | 2009-01-20 | 2012-07-12 | ファイザー・インク | 置換ピラジノンアミド |
| UA99882C2 (uk) | 2009-03-11 | 2012-10-10 | Пфайзер Інк. | Похідні бензофуранілу, фармацевтична композиція та спосіб лікування захворювань (варіанти) |
| UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| WO2011044185A2 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
| WO2011044187A1 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| WO2011044184A1 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
| CA2777739A1 (en) | 2009-10-16 | 2011-04-21 | Rib-X Pharmaceuticals, Inc. | Antimicrobial compounds and methods of making and using the same |
| EA023350B1 (ru) | 2009-10-16 | 2016-05-31 | Мелинта Терапьютикс, Инк. | Противомикробные соединения, способы их получения и применение |
| JPWO2011071135A1 (ja) | 2009-12-11 | 2013-04-22 | 塩野義製薬株式会社 | オキサジン誘導体 |
| CA2816285A1 (en) | 2010-10-29 | 2012-05-03 | Shionogi & Co., Ltd. | Naphthyridine derivative |
| EP2634188A4 (en) | 2010-10-29 | 2014-05-07 | Shionogi & Co | FUSIONED AMINODIHYDROPYRIMIDINE DERIVATIVE |
| US9221839B2 (en) | 2011-04-07 | 2015-12-29 | Merck Sharp & Dohme Corp. | C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
| US9145426B2 (en) | 2011-04-07 | 2015-09-29 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
| TW201247635A (en) | 2011-04-26 | 2012-12-01 | Shionogi & Co | Oxazine derivatives and a pharmaceutical composition for inhibiting BAC1 containing them |
| EP2747769B1 (en) | 2011-08-22 | 2017-08-02 | Merck Sharp & Dohme Corp. | 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use |
| EP2773207B1 (en) * | 2011-10-31 | 2018-03-07 | Merck Sharp & Dohme Corp. | Aminopyrimidinones as interleukin receptor-associated kinase inhibitors |
| JP2016501827A (ja) | 2012-10-24 | 2016-01-21 | 塩野義製薬株式会社 | Ｂａｃｅ１阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体 |
| CA2923179A1 (en) | 2013-09-09 | 2015-03-12 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
| KR20160070066A (ko) | 2013-09-09 | 2016-06-17 | 멜린타 테라퓨틱스, 인크. | 항균 화합물, 및 이의 제조 방법 및 이용 방법 |
| SG11201707346RA (en) | 2015-03-11 | 2017-10-30 | Melinta Therapeutics Inc | Antimicrobial compounds and methods of making and using the same |
| EP3452479A1 (en) | 2016-05-06 | 2019-03-13 | Melinta Therapeutics, Inc. | Antimicrobials and methods of making and using same |
| WO2020163689A1 (en) | 2019-02-08 | 2020-08-13 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | 20-hete formation inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4625026A (en) * | 1982-12-30 | 1986-11-25 | Biomeasure, Inc. | 2-amino-4-oxo-tricyclicpyrimidines having antiviral activities against herpes simplex virus type II infections |
| EP0905136A1 (en) * | 1997-09-08 | 1999-03-31 | Janssen Pharmaceutica N.V. | Tetrahydro gamma-carbolines |
| TWI241298B (en) * | 1998-09-25 | 2005-10-11 | Mitsubishi Chem Corp | Pyrimidone derivatives |
| EP1261327B1 (en) * | 2000-02-25 | 2005-04-27 | F.Hoffmann-La Roche Ag | Adenosine receptor modulators |
| US6777420B2 (en) * | 2001-06-15 | 2004-08-17 | Microbiotix, Inc. | Heterocyclic antibacterial compounds |
| US20030114445A1 (en) * | 2001-06-15 | 2003-06-19 | Chengxin Zhi | N3-substituted 6-anilinopyrimidines and methods to treat-Gram-positive bacterial and mycoplasmal infections |
| US6951875B2 (en) * | 2001-10-29 | 2005-10-04 | Hoffmann-La Roche Inc. | Conjugated aromatic compounds with a pyridine substituent |
| AU2002950853A0 (en) * | 2002-08-19 | 2002-09-12 | Fujisawa Pharmaceutical Co., Ltd. | Aminopyrimidine compound and pharmaceutical use thereof |
| US7592348B2 (en) * | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| EP2153832B1 (en) * | 2003-12-15 | 2016-03-09 | Merck Sharp & Dohme Corp. | Heterocyclic aspartyl protease inhibitors |
| AR054619A1 (es) * | 2005-06-14 | 2007-07-04 | Schering Corp | Inhibidores de aspartil proteasas |
| JP2008543841A (ja) * | 2005-06-14 | 2008-12-04 | シェーリング コーポレイション | 大環状複素環式アスパルチルプロテアーゼインヒビター |
| US7763606B2 (en) * | 2005-10-27 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| JP2009513670A (ja) * | 2005-10-31 | 2009-04-02 | シェーリング コーポレイション | アスパルチルプロテアーゼインヒビター |
-
2006
- 2006-11-13 US US12/093,670 patent/US20090215801A9/en not_active Abandoned
- 2006-11-13 JP JP2008541107A patent/JP2009515949A/ja active Pending
- 2006-11-13 WO PCT/SE2006/001280 patent/WO2007058580A1/en not_active Ceased
- 2006-11-13 CN CNA200680051085XA patent/CN101360720A/zh active Pending
- 2006-11-13 EP EP06813003A patent/EP1951680A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009515949A5 (OSRAM) | ||
| JP2009520685A5 (OSRAM) | ||
| EP2485920B1 (en) | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use | |
| US7425552B2 (en) | Pyridazinone compounds | |
| JP2013544893A5 (OSRAM) | ||
| CA2654405A1 (en) | Amino-imidazolones and their use as a medicament for treating cognitive impairment, alzheimer disease, neurodegeneration and dementia | |
| JP2010524942A5 (OSRAM) | ||
| RU2013138717A (ru) | Конденсированные производные аминодигидротиазина, пригодные в качестве ингибиторов васе | |
| JP2006522747A5 (OSRAM) | ||
| RU2007132262A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназ | |
| NZ594332A (en) | Compounds for the prevention and treatment of cardiovascular disease | |
| JP2014037426A5 (OSRAM) | ||
| CN101263130A (zh) | 2-苯胺-4-芳基取代的噻唑衍生物 | |
| JP2014526549A5 (OSRAM) | ||
| JP2008500992A5 (OSRAM) | ||
| WO2007134107A3 (en) | Cold menthol receptor-1 antagonists | |
| RU2009123525A (ru) | ПРОИЗВОДНЫЕ 5-СУЛЬФАНИЛМЕТИЛ[1,2,4}ТРИАЗОЛ[1,5-а]ПИРИМИДИН-7-ОЛА В КАЧЕСТВЕ АНТАГОНИСТОВ CXCR2 | |
| CA2981499A1 (en) | Methods of administering glutaminase inhibitors | |
| MY148375A (en) | Delta and epsilon crystal forms of imatinib mesylate | |
| ES2222396T3 (es) | Compuestos utiles como ingrediente activo de un medicamento para el tratamiento preventivo y/o terapeutico de enfermedades neurodegenerativas. | |
| JP2012530758A5 (OSRAM) | ||
| WO2007056219A3 (en) | [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto | |
| CA2604017A1 (en) | Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives | |
| JP2017513887A5 (OSRAM) | ||
| JP2020503293A5 (OSRAM) |